Equine herpesvirus type 1 modified live virus vaccines: quo vaditis?

References

• Minson AC et al. Herpesviridae. In: Virus Taxonomy. Van Regenmortel MH (Ed.), Academic Press, New York, NY, USA, 203–225 (2000).
   Google Scholar
• Gilkerson JR, Whalley JM, Drummer HE, Studdert MJ, Love DN. Epidemiology of EHV-1 and EHV-4 in the mare and foal populations on a Hunter Valley stud farm: are mares the source of EHV-1 for unweaned foals. Vet. Microbiol. 68, 27–34 (1999).
   PubMed Web of Science ®Google Scholar
• Gilkerson JR, Whalley JM, Drummer HE, Studdert MJ, Love DN. Epidemiological studies of equine herpesvirus 1 (EHV-1) in thoroughbred foals: a review of studies conducted in the Hunter Valley of New South Wales between 1995 and 1997. Vet. Microbiol. 68, 15–25 (1999).
   PubMed Web of Science ®Google Scholar
• Gilkerson JR, Love DN, Drummer HE, Studdert MJ, Whalley JM. Seroprevalence of equine herpesvirus 1 in thoroughbred foals before and after weaning. Aust. Vet. J. 76, 677–682 (1998).
   PubMed Web of Science ®Google Scholar
• Doll ER, Bryans JT. Epizootiology of equine viral rhinopneumonitis. J. Am. Vet. Med. Assoc. 142, 31–37 (1963).
   PubMed Web of Science ®Google Scholar
• O’Callaghan DJ, Osterrieder N. The equine herpesviruses. In: Encyclopedia of Virology. Webster RG, Granoff A (Eds.), Academic Press, Harcourt Brace & Co., San Diego, CA, USA (1999).
   Google Scholar
• Kydd JH, Smith KC, Hannant D, Livesay GJ, Mumford JA. Distribution of equid herpesvirus-1 (EHV-1) in respiratory tract associated lymphoid tissue: implications for cellular immunity. Equine Vet. J. 26, 470–473 (1994).
   PubMed Web of Science ®Google Scholar
• Kydd JH, Smith KC, Hannant D, Livesay GJ, Mumford JA. Distribution of equid herpesvirus-1 (EHV-1) in the respiratory tract of ponies: implications for vaccination strategies. Equine Vet. J. 26, 466–469 (1994).
   PubMed Web of Science ®Google Scholar
• Hannant D, O’Neill T, Ostlund EN, Kydd JH, Hopkin PJ, Mumford JA. Equid herpesvirus-induced immunosuppression is associated with lymphoid cells and not soluble circulating factors. Viral Immunol. 12, 313–321 (1999).
   PubMed Web of Science ®Google Scholar
• Platt H, Singh H, Whitwell KE. Pathological observations on an outbreak of paralysis in broodmares. Equine Vet. J. 12, 118–126 (1980).
   PubMed Web of Science ®Google Scholar
• Edington N, Bridges CG, Patel JR. Endothelial cell infection and thrombosis in paralysis caused by equid herpesvirus-1: equine stroke. Arch. Virol. 90, 111–124 (1986).
   PubMed Web of Science ®Google Scholar
• Baxi MK, Borchers K, Bartels T, Schellenbach A, Baxi S, Field HJ. Molecular studies of the acute infection, latency and reactivation of equine herpesvirus-1 (EHV-1) in the mouse model. Virus Res. 40, 33–45 (1996).
   PubMed Web of Science ®Google Scholar
• Welch HM, Bridges CG, Lyon AM, Griffiths L, Edington N. Latent equid herpesviruses 1 and 4: detection and distinction using the polymerase chain reaction and co-cultivation from lymphoid tissues. J. Gen. Virol. 73, 261–268 (1992).
   PubMed Web of Science ®Google Scholar
• Allen GP, Bryans JT. Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections. Prog. Vet. Microbiol. Immunol. 2, 78–144 (1986).
   PubMedGoogle Scholar
• Mumford JA, Rossdale PD, Jessett DM, Gann SJ, Ousey J, Cook RF. Serological and virological investigations of an equid herpesvirus 1 (EHV-1) abortion storm on a stud farm in 1985. J. Reprod. Fertil. 35 (Suppl.), 509–518 (1987).
   Google Scholar
• Wilson WD. Equine herpesvirus 1 myeloencephalopathy. Vet. Clin. North Am. Equine Pract. 13, 53–72 (1997).
   PubMed Web of Science ®Google Scholar
• Ostlund EN. The equine herpesviruses. Vet. Clin. North Am. Equine Pract. 9, 283–294 (1993).
   PubMed Web of Science ®Google Scholar
• Tearle JP, Smith KC, Platt AJ, Hannant D, Davis-Poynter NJ, Mumford JA. In vitro characterisation of high and low virulence isolates of equine herpesvirus-1 and -4. Res. Vet. Sci. 75, 83–86 (2003).
   PubMed Web of Science ®Google Scholar
• Whitwell KE, Blunden AS. Pathological findings in horses dying during an outbreak of the paralytic form of Equid herpesvirus Type 1 (EHV-1) infection. Equine Vet. J. 24, 13–19 (1992).
   PubMed Web of Science ®Google Scholar
• Allen G, Powell D. Equine herpesvirus neurological disease in the USA and United Kingdom. Equine Dis. Quart. 12, 2–3 (2003).
   Google Scholar
• Bryans JT, Crowe ME, Doll ER, McCollum WH. Isolation of a filterable agent causing arteritis of horses and abortion by mares; its differentiation from the equine abortion (influenza) virus. Cornell Vet. 47, 3–41 (1957).
   PubMedGoogle Scholar
• Dimock WW, Edwards PR. Is there a filterable virus of abortion in mares? Kentucky Ag. Exp. Station Bull. 333, 297–301 (1932).
   Google Scholar
• Anderson E, Goodpasture EW. Infection of newborn Syrian hamsters with the virus of mare abortion (Dimock and Edwards). Am. J. Pathol. 18, 555–561 (1942).
   PubMedGoogle Scholar
• Randall CC, Ryden FW, Doll ER, Schell FS. Cultivation of equine abortion virus in fetal horse tissue in vitro. Am. J. Pathol. 29, 139–153 (1953).
   Google Scholar
• Arhelger RB, Darlington RW, Randall CC. An electron microscopic study of equine abortion virus infection in hamster liver. Am. J. Pathol. 42, 703–713 (1963).
   PubMed Web of Science ®Google Scholar
• Darlington RW, Randall CC. The nucleic acid content of equine abortion virus. Virology 19, 322–327 (1963).
   PubMed Web of Science ®Google Scholar
• Randall CC. Adaptation of equine abortion virus to HeLa cells. Proc. Soc. Exp. Biol. Med. 95, 508–510 (1957).
   PubMed Web of Science ®Google Scholar
• Doll ER, Crowe ME, Bryans JT, McCollum WH. Infection immunity in equine virus abortion. Cornell Vet. 45, 387–410 (1955).
   PubMedGoogle Scholar
• Doll ER, Bryans JT, McCollum WH. A procedure for evaluating the antigenicity of killed virus vaccines for equine rhinopneumonitis. Cornell Vet. 49, 212–220 (1959).
   PubMedGoogle Scholar
• Doll ER, Wallace ME, Bryans JT, Richards MG. Complement-fixation antibody response following administration of equine virus abortion vaccine. Am. J. Vet. Res. 14, 46–48 (1953).
   PubMed Web of Science ®Google Scholar
• Doll ER, Bryans JT. A planned infection program for immunizing mares against viral rhinopneumonitis. Cornell Vet. 53, 249–262 (1963).
   PubMedGoogle Scholar
• Doll ER, Bryans JT. Immunization of young horses against viral rhinopneumonitis. Cornell Vet. 53, 24–41 (1963).
   PubMedGoogle Scholar
• Hübert PH, Birkenmaier S, Rziha HJ, Osterrieder N. Alterations in the equine herpesvirus type-1 (EHV-1) strain RacH during attenuation. Zentralbl. Veterinarmed. [B] 43, 1–14 (1996).
   PubMedGoogle Scholar
• Mayr A, Bohm HO, Brill J, Woyciechowska S. Characterization of an equine abortion virus from Poland and comparison with known equine rhinopneumonitis virus strains]. Arch. Gesamte Virusforsch. 17, 216–230 (1965).
   PubMedGoogle Scholar
• Mayr A, Pette J, Petzoldt K, Wagener K. Studies on the development of a live vaccine against rhinopneumonitis (mare abortion) of horses. Zentralbl. Veterinarmed. (B) 15, 406–418 (1968).
   Google Scholar
• Reczko E, Mayr A. On the fine structure of a virus of the herpes group isolated from horses (short report). Arch. Gesamte Virusforsch. 13, 591–593 (1963).
   PubMedGoogle Scholar
• Allen G, Yeargan M, Costa LR, Cross R. Major histocompatibility complex class I-restricted cytotoxic T-lymphocyte responses in horses infected with equine herpesvirus 1. J. Virol. 69, 606–612 (1995).
   PubMed Web of Science ®Google Scholar
• O’ Neill T, Kydd JH, Allen GP, Wattrang E, Mumford JA, Hannant D. Determination of equid herpesvirus 1-specific, CD8+, cytotoxic T-lymphocyte precursor frequencies in ponies. Vet. Immunol. Immunopathol. 70, 43–54 (1999).
   PubMed Web of Science ®Google Scholar
• Soboll G, Whalley JM, Koen MT et al. Identification of equine herpesvirus-1 antigens recognized by cytotoxic T-lymphocytes. J. Gen. Virol. 84, 2625–2634 (2003).
   PubMed Web of Science ®Google Scholar
• Burki F, Rossmanith W, Nowotny N, Pallan C, Mostl K, Lussy H. Viraemia and abortions are not prevented by two commercial equine herpesvirus-1 vaccines after experimental challenge of horses. Vet. Q. 12, 80–86 (1990).
   PubMed Web of Science ®Google Scholar
• Allen GP, Yeargan MR, Bryans JT. Alterations in the equine herpesvirus 1 genome after in vitro and in vivo virus passage. Infect. Immunol. 40, 436–439 (1983).
   PubMed Web of Science ®Google Scholar
• Holmes MA, Townsend HGG, Hussey S et al. Immune responses to commercial equine vaccines. AAEP Proceedings 49, 224–226 (2003).
   Google Scholar
• Townsend HGG, Lunn DP, Bogdan J, Griffin S, Holland R, Barnett C. Comparative efficacy of commercial vaccines in naive horses: serologic responses and protection after influenza challenge. AAEP Proceedings 49, 227–229 (2003).
   Google Scholar
• Minke JM, Audonnet JC, Fischer L. Equine viral vaccines: the past, present and future. Vet. Res. 35, 425–443 (2004).
   PubMed Web of Science ®Google Scholar
• Foote CE, Love DN, Gilkerson JR et al. Serum antibody responses to equine herpesvirus 1 glycoprotein D in horses, pregnant mares and young foals. Vet. Immunol. Immunopathol. 105, 47–57 (2005).
   PubMed Web of Science ®Google Scholar
• Ruitenberg KM, Love DN, Gilkerson JR, Wellington JE, Whalley JM. Equine herpesvirus 1 (EHV-1) glycoprotein D DNA inoculation in horses with pre-existing EHV-1/EHV-4 antibody. Vet. Microbiol. 76, 117–127 (2000).
   PubMed Web of Science ®Google Scholar
• Ruitenberg KM, Walker C, Love DN, Wellington JE, Whalley JM. A prime–boost immunization strategy with DNA and recombinant baculovirus-expressed protein enhances protective immunogenicity of glycoprotein D of equine herpesvirus 1 in naive and infection-primed mice. Vaccine 18, 1367–1373 (2000).
   PubMed Web of Science ®Google Scholar
• Osterrieder N, Wagner R, Brandmuller C, Schmidt P, Wolf H, Kaaden OR. Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB). Virology 208, 500–510 (1995).
   PubMed Web of Science ®Google Scholar
• Jacobs L, Mulder WA, van Oirschot JT, Gielkens AL, Kimman TG. Deleting two amino acids in glycoprotein gI of pseudorabies virus decreases virulence and neurotropism for pigs, but does not affect immunogenicity. J. Gen. Virol. 74 (Pt. 10), 2201–2206 (1993).
   PubMed Web of Science ®Google Scholar
• van Engelenburg FA, Kaashoek MJ, Rijsewijk FA et al. A glycoprotein E deletion mutant of bovine herpesvirus 1 is avirulent in calves. J. Gen. Virol. 75, 2311–2318 (1994).
   PubMed Web of Science ®Google Scholar
• Arvin AM. Varicella vaccine - the first six years. N. Engl. J Med. 344, 1007–1009 (2001).
   PubMed Web of Science ®Google Scholar
• Witter RL. Marek’s Disease. In: Protective efficacy of Marek’s disease Vaccines. Hirai, K. (Ed.) Springer, NY, USA, 57–90 (2001).
   Google Scholar
• Goodman LB, Wagner B, Flaminio J et al. Comparison of the efficacy of modified-live and inactivated vaccines against challenge with equine herpesvirus Type 1 (EHV-1) (In Press) (2005).
   Google Scholar
• Breathnach CC, Yeargan MR, Sheoran AS, Allen GP. The mucosal humoral immune response of the horse to infective challenge and vaccination with equine herpesvirus-1 antigens. Equine Vet. J. 33, 651–657 (2001).
   PubMed Web of Science ®Google Scholar
• Mayr A, Pette J. 1st experiments concerning the vaccination of horses against rhino- pneumonia (viral abortion of mares) with a live vaccine from cell cultures. Bull. Off. Int. Epizoot. 70, 133–140 (1968).
   PubMedGoogle Scholar
• Neubauer A, Braun B, Brandmuller C, Kaaden OR, Osterrieder N. Analysis of the contributions of the equine herpesvirus 1 glycoprotein gB homolog to virus entry and direct cell-to-cell spread. Virology 227, 281–294 (1997).
   PubMed Web of Science ®Google Scholar
• Osterrieder N, Neubauer A, Brandmuller C, Kaaden OR, O’Callaghan DJ. The equine herpesvirus 1 IR6 protein influences virus growth at elevated temperature and is a major determinant of virulence. Virology 226, 243–251 (1996).
   PubMed Web of Science ®Google Scholar
• Osterrieder N, Neubauer A, Brandmuller C, Kaaden OR, O’Callaghan DJ. The equine herpesvirus 1 IR6 protein that colocalizes with nuclear lamins is involved in nucleocapsid egress and migrates from cell to cell independently of virus infection. J. Virol. 72, 9806–9817 (1998).
   PubMed Web of Science ®Google Scholar
• Osterrieder N, Holden VR, Brandmuller C, Neubauer A, Kaaden OR, O’Callaghan DJ. The equine herpesvirus 1 IR6 protein is nonessential for virus growth in vitro and modified by serial virus passage in cell culture. Virology 217, 442–451 (1996).
   PubMed Web of Science ®Google Scholar
• Meyer H, Hubert P, Schwend C, Eichhorn W. Rapid identification and differentiation of the vaccine strain Rac H from EHV 1 field isolates using a non-radioactive DNA probe. Vet. Microbiol. 30, 13–20 (1992).
   PubMed Web of Science ®Google Scholar
• Osterrieder N, Hubert PH, Brandmuller C, Kaaden OR. A touchdown PCR for the differentiation of equine herpesvirus Type 1 (EHV-1) field strains from the modified live vaccine strain RacH. J. Virol. Methods 50, 129–136 (1994).
   PubMed Web of Science ®Google Scholar
• O’Callaghan DJ, Cheevers WP, Gentry GA, Randall CC. Kinetics of cellular and viral DNA synthesis in equine abortion (herpes) virus infection of L-M cells. Virology 36, 104–114 (1968).
   PubMed Web of Science ®Google Scholar
• Randall CC, Bracken EC. Studies on hepatitis in hamsters infected with equine abortion virus. I. Sequential development of inclusions and the growth cycle. Am. J. Pathol. 33, 709–727 (1957).
   PubMed Web of Science ®Google Scholar
• Randall CC, Lawson LA. Adaptation of equine abortion virus to Earle’s L cells in serum-free medium with plaque formation. Proc. Soc. Exp. Biol. Med. 110, 487–489 (1962).
   PubMed Web of Science ®Google Scholar
• Colle CF, III, Flowers CC, O’Callaghan DJ. Open reading frames encoding a protein kinase, homolog of glycoprotein gX of pseudorabies virus, and a novel glycoprotein map within the unique short segment of equine herpesvirus Type 1. Virology 188, 545–557 (1992).
   PubMed Web of Science ®Google Scholar
• Colle CF, III, O’Callaghan DJ. Transcriptional analyses of the unique short segment of EHV-1 strain Kentucky A. Virus Genes 9, 257–268 (1995).
   PubMed Web of Science ®Google Scholar
• Flowers CC, O’Callaghan DJ. The equine herpesvirus Type 1 (EHV-1) homolog of herpes simplex virus Type 1 US9 and the nature of a major deletion within the unique short segment of the EHV-1 KyA strain genome. Virology 190, 307–315 (1992).
   PubMed Web of Science ®Google Scholar
• Telford EA, Watson MS, McBride K, Davison AJ. The DNA sequence of equine herpesvirus-1. Virology 189, 304–316 (1992).
   PubMed Web of Science ®Google Scholar
• Yalamanchili RR, O’Callaghan DJ. Sequence and organization of the genomic termini of equine herpesvirus Type 1. Virus Res. 15, 149–161 (1990).
   PubMed Web of Science ®Google Scholar
• McGeoch DJ, Moss HW, McNab D, Frame MC. DNA sequence and genetic content of the HindIII l region in the short unique component of the herpes simplex virus Type 2 genome: identification of the gene encoding glycoprotein G, and evolutionary comparisons. J. Gen. Virol. 68, 19–38 (1987).
   PubMed Web of Science ®Google Scholar
• Rudolph J, O’Callaghan DJ, Osterrieder N. Cloning of the genomes of equine herpesvirus Type 1 (EHV-1) strains KyA and RacL11 as bacterial artificial chromosomes (BAC). J. Vet. Med. B Infect. Dis. Vet. Public Health 49, 31–36 (2002).
   PubMedGoogle Scholar
• Flowers CC, Eastman EM, O’Callaghan DJ. Sequence analysis of a glycoprotein D gene homolog within the unique short segment of the EHV-1 genome. Virology 180, 175–184 (1991).
   PubMed Web of Science ®Google Scholar
• von Einem J, Wellington J, Whalley JM, Osterrieder K, O’Callaghan DJ, Osterrieder N. The truncated form of glycoprotein gp2 of equine herpesvirus 1 (EHV-1) vaccine strain KyA is not functionally equivalent to full-length gp2 encoded by EHV-1 wild type strain RacL11. J. Virol. 78, 3003–3013 (2004).
   PubMed Web of Science ®Google Scholar
• Smith PM, Kahan SM, Rorex CB, von Einem J, Osterrieder N, O’Callaghan DJ. Expression of the full-length form of gp2 of equine herpesvirus 1 (EHV-1) completely restores respiratory virulence to the attenuated EHV-1 strain KyA in CBA mice. J. Virol. 79, 5105–5115 (2005).
   PubMed Web of Science ®Google Scholar
• Matsumura T, O’Callaghan DJ, Kondo T, Kamada M. Lack of virulence of the murine fibroblast adapted strain, Kentucky A (KyA), of equine herpesvirus Type 1 (EHV-1) in young horses. Vet. Microbiol. 48, 353–365 (1996).
   PubMed Web of Science ®Google Scholar
• Matsumura T, Kondo T, Sugita S, Damiani AM, O’Callaghan DJ, Imagawa H. An equine herpesvirus Type 1 recombinant with a deletion in the gE and gI genes is avirulent in young horses. Virology 242, 68–79 (1998).
   PubMed Web of Science ®Google Scholar
• Frampton AR, Smith PM, Zhang Y, Matsumura T, Osterrieder N, O’CallaghanDJ. Contribution of gene products encoded within the unique short segment of equine herpesvirus 1 to virulence in a murine model. Virus Res. 90, 287–301 (2002).
   PubMed Web of Science ®Google Scholar
• Rudolph J, Osterrieder N. Equine Herpesvirus Type 1 devoid of gM and gp2 is severely impaired in virus egress but not direct cell-to-cell spread. Virology 293, 356–367 (2002).
   PubMed Web of Science ®Google Scholar
• Patel JR, Didlick S, Bateman H. Efficacy of a live equine herpesvirus-1 (EHV-1) strain C147 vaccine in foals with maternally-derived antibody: protection against EHV-1 infection. Equine Vet. J. 36, 447–451 (2004).
   PubMed Web of Science ®Google Scholar
• Patel JR, Foldi J, Bateman H, Williams J, Didlick S, Stark R. Equid herpesvirus (EHV-1) live vaccine strain C147: efficacy against respiratory diseases following EHV types 1 and 4 challenges. Vet. Microbiol. 92, 1–17 (2003).
   PubMed Web of Science ®Google Scholar
• Patel JR, Bateman H, Williams J, Didlick S. Derivation and characterisation of a live equid herpes virus-1 (EHV-1) vaccine to protect against abortion and respiratory disease due to EHV-1. Vet. Microbiol. 91, 23–39 (2003).
   PubMed Web of Science ®Google Scholar
• Osterrieder N, Neubauer A, Brandmuller C, Braun B, Kaaden OR, Baines JD. The equine herpesvirus 1 glycoprotein gp21/22a, the herpes simplex virus Type 1 gM homolog, is involved in virus penetration and cell-to-cell spread of virions. J. Virol. 70, 4110–4115 (1996).
   PubMed Web of Science ®Google Scholar
• Sun Y, Brown SM. The open reading frames 1, 2, 71, and 75 are nonessential for the replication of equine herpesvirus Type 1 in vitro. Virology 199, 448–452 (1994).
   PubMed Web of Science ®Google Scholar
• Nicolson L, Rafferty EL, Brawley A, Onions DE. An improved cosmid vector for the cloning of equine herpesvirus DNA. Gene 150, 405–406 (1994).
   PubMed Web of Science ®Google Scholar
• Fitzmaurice T, Walker C, Kukreja A, Sun Y, Brown SM, Field HJ. The pathogenesis of ED71, a defined deletion mutant of equine herpesvirus-1, in a murine intranasal infection model for equine abortion. J. Gen. Virol. 78, 2167–2169 (1997).
   PubMed Web of Science ®Google Scholar
• Marshall KR, Sun Y, Brown SM, Field HJ. An equine herpesvirus-1 gene 71 deletant is attenuated and elicits a protective immune response in mice. Virology 231, 20–27 (1997).
   PubMed Web of Science ®Google Scholar
• Neubauer A, Beer M, Brandmuller C, Kaaden OR, Osterrieder N. Equine herpesvirus 1 mutants devoid of glycoprotein B or M are apathogenic for mice but induce protection against challenge infection. Virology 239, 36–45 (1997).
   PubMed Web of Science ®Google Scholar
• Osterrieder N. Construction and characterization of an equine herpesvirus 1 glycoprotein C negative mutant. Virus Res. 59, 165–177 (1999).
   PubMed Web of Science ®Google Scholar
• Osterrieder N, Seyboldt C, Elbers K. Deletion of gene 52 encoding glycoprotein M of equine herpesvirus Type 1 strain RacH results in increased immunogenicity. Vet. Microbiol. 81, 219–226 (2001).
   PubMed Web of Science ®Google Scholar
• Osterrieder N, Schumacher D, Trapp S, Beer M, von Einem J, Tischer K. Generation and exploitation of infectious bacterial artificial chromosome (BAC) clones of animal herpesviruses. Berl. Munch. Tierarztl. Wochenschr. 116, 373–380 (2003).
   PubMed Web of Science ®Google Scholar
• Rudolph J, Seyboldt C, Granzow H, Osterrieder N. The gene 10 (UL49.5) product of equine herpesvirus 1 is necessary and sufficient for functional processing of glycoprotein M. J. Virol. 76, 2952–2963 (2002).
   PubMed Web of Science ®Google Scholar
• Bryant NA, Davis-Poynter N, Vanderplasschen A, Alcami A. Glycoprotein G isoforms from some alphaherpesviruses function as broad spectrum chemokine binding proteins. EMBO J. 22, 833–846 (2003).
   PubMed Web of Science ®Google Scholar
• Koppers-Lalic D, Reits EA, Ressing ME et al. Varicelloviruses avoid T-cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing. Proc. Natl Acad. Sci. USA 102, 5144–5149 (2005).
   PubMed Web of Science ®Google Scholar
• Abaitua F, Rodriguez JR, Garzon A, Rodriguez D, Esteban M. Improving recombinant MVA immune responses: Potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-γ. Virus Res. (2005).
   PubMedGoogle Scholar
• Aleshin SE, Timofeev AV, Khoretonenko MV et al. Combined prime–boost vaccination against tick-borne encephalitis (TBE) using a recombinant vaccinia virus and a bacterial plasmid both expressing TBE virus non-structural NS1 protein. BMC. Microbiol. 5, 45 (2005).
   PubMedGoogle Scholar
• Rupprecht CE, Hanlon CA, Blanton J et al. Oral vaccination of dogs with recombinant rabies virus vaccines. Virus Res. 111, 101–105 (2005).
   PubMed Web of Science ®Google Scholar
• Smee DF, Bailey KW, Wong MH, Wandersee MK, Sidwell RW. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J. Infect. Dis. 190, 1132–1139 (2004).
   PubMed Web of Science ®Google Scholar
• Kanesa-Thasan N, Smucny JJ, Hoke CH et al. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 19, 483–491 (2000).
   PubMed Web of Science ®Google Scholar
• Maguire CA, Sapinoro R, Girgis N et al. Recombinant adenovirus Type 5 vectors that target DC-SIGN, ChemR23 and α(v)β(3) integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens. Vaccine (2005).
   PubMedGoogle Scholar
• Gardlik R, Palffy R, Hodosy J, Lukacs J, Turna J, Celec P. Vectors and delivery systems in gene therapy. Med. Sci. Monit. 11, RA110–RA121 (2005) (In Press).
   PubMed Web of Science ®Google Scholar
• Campbell, EM, Hope, TJ. Gene therapy progress and prospects: viral trafficking during infection. Gene Ther. 12, 1353–1359 (2005).
   PubMed Web of Science ®Google Scholar
• Lauterbach H, Ried C, Epstein AL, Marconi P, Brocker T. Reduced immune responses after vaccination with a recombinant herpes simplex virus Type 1 vector in the presence of antiviral immunity. J. Gen. Virol. 86, 2401–2410 (2005).
   PubMed Web of Science ®Google Scholar
• Trapp S, von Einem J, Hofmann H et al. Potential of equine herpesvirus 1 as a vector for immunization. J. Virol. 79, 5445–5454 (2005).
   PubMed Web of Science ®Google Scholar
• Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5, 558–567 (2005).
   PubMed Web of Science ®Google Scholar
• Bolin SR, Ridpath JF. Glycoprotein E2 of bovine viral diarrhea virus expressed in insect cells provides calves limited protection from systemic infection and disease. Arch. Virol. 141, 1463–1477 (1996).
   PubMed Web of Science ®Google Scholar
• Tischer BK, von Einem J, Kaufer B, Osterrieder N. Two-step Red-mediated recombination for versatile, high-efficiency markerless DNA manipulation in Escherichia coli. BioTechniques, (2006) (In Press).
   PubMedGoogle Scholar